1. Home
  2. CGON vs HTZ Comparison

CGON vs HTZ Comparison

Compare CGON & HTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGON
  • HTZ
  • Stock Information
  • Founded
  • CGON 2010
  • HTZ 1918
  • Country
  • CGON United States
  • HTZ United States
  • Employees
  • CGON N/A
  • HTZ N/A
  • Industry
  • CGON
  • HTZ Rental/Leasing Companies
  • Sector
  • CGON
  • HTZ Consumer Discretionary
  • Exchange
  • CGON NYSE
  • HTZ Nasdaq
  • Market Cap
  • CGON 2.1B
  • HTZ 2.0B
  • IPO Year
  • CGON 2024
  • HTZ 1997
  • Fundamental
  • Price
  • CGON $26.90
  • HTZ $7.29
  • Analyst Decision
  • CGON Strong Buy
  • HTZ Sell
  • Analyst Count
  • CGON 10
  • HTZ 8
  • Target Price
  • CGON $64.44
  • HTZ $4.45
  • AVG Volume (30 Days)
  • CGON 864.2K
  • HTZ 6.9M
  • Earning Date
  • CGON 08-07-2025
  • HTZ 08-07-2025
  • Dividend Yield
  • CGON N/A
  • HTZ N/A
  • EPS Growth
  • CGON N/A
  • HTZ N/A
  • EPS
  • CGON N/A
  • HTZ N/A
  • Revenue
  • CGON $662,000.00
  • HTZ $8,782,000,000.00
  • Revenue This Year
  • CGON N/A
  • HTZ N/A
  • Revenue Next Year
  • CGON $25,206.93
  • HTZ $2.42
  • P/E Ratio
  • CGON N/A
  • HTZ N/A
  • Revenue Growth
  • CGON 224.51
  • HTZ N/A
  • 52 Week Low
  • CGON $14.80
  • HTZ $2.47
  • 52 Week High
  • CGON $40.47
  • HTZ $9.39
  • Technical
  • Relative Strength Index (RSI)
  • CGON 59.29
  • HTZ 59.71
  • Support Level
  • CGON $25.51
  • HTZ $6.60
  • Resistance Level
  • CGON $27.28
  • HTZ $8.03
  • Average True Range (ATR)
  • CGON 1.01
  • HTZ 0.48
  • MACD
  • CGON 0.02
  • HTZ 0.09
  • Stochastic Oscillator
  • CGON 89.23
  • HTZ 67.97

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

About HTZ Hertz Global Holdings Inc

Hertz Global Holdings Inc is engaged principally in the business of renting vehicles through Hertz, Dollar and Thrifty brands. The Company has identified two reportable segments: Americas RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in the U.S., Canada, Latin America and the Caribbean; International RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in locations other than the U.S., Canada, Latin America and the Caribbean. The Company maintain a substantial network of company-operated rental locations, a majority of which are in Europe, and have franchisees and partners that operate rental locations under brands. Geographical markets includes U.S., Europe, Pacific Asia, Middle East and Africa, Latin America.

Share on Social Networks: